Prostate cancer market will treble to $8.2 billion by 2023, says GlobalData
The global treatment market value for prostate cancer will expand more than threefold from $2.6 billion in 2013 to an estimated $8.2 billion by 2023, according to research and consulting firm GlobalData.
This increase, excluding hormonal and bone therapies, will occur across the nine major markets of the USA, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada, and will be driven by a rapidly aging population. Japan and Brazil will experience particularly impressive market growth during the forecast period, due to the increased screening of prostate cancer resulting in higher incidence in Japan, as well as the introduction of several branded products for the treatment of castration-resistant prostate cancer (CRPC).
Zytiga and Xtandi to drive growth
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze